-
- About PMI
-
Smoke-free approach
- Harm Reduction
- Absence of Combustion
- Nicotine
- Tar
- Tobacco Regulation
- Harmful Chemicals Measured
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- PMI’s Studies on Smoke-Free Products
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Investigator Initiated Studies (IIS)
- Facts and Figures on Our Smoke-Free Future
ResearchExplore our product assessment program, its results, and the publications where they are published. Find a wealth of independent research and expert reports.Read More -
Our Products
- Heated Tobacco Products
- E-cigarettes and Vaping Products
- Oral Nicotine Pouches
- Nicotine Salts Product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
In Vitro Systems Toxicology Assessment of Exposure to Aerosol from a Carbon Heated Tobacco Product as Compared with Exposure to Cigarette Smoke: The Impact on Nasal and Small Airway Epithelial Cultures
Iskandar, A. R.; Martinez, Y.; Mathis, C.; Leroy, P.; Martin, F.; Sewer, A.; Ortega Torres, L.; Majeed, S.; Trivedi, K.; Frentzel, S.; Guedj, E.; Merg, C.; Elamin, A.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.
No abstract available.
Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products
An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models
Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses
Quantitative Modeling of In Vitro Data Using an Adverse Outcome Pathway for the Risk Assessment of Decreased Lung Function in Humans
Systems toxicology: The future of risk assessment
Systems biology: Methods and applications
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.